Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director | February 05, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date February 05, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par valueSEC Table I · non-derivative | Direct | 32,655 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 16,600 · Balance 32,655 F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2: Includes shares of common stock underlying unvested restricted stock units. F3: The number of reported securities has been adjusted to reflect prior reverse stock splits. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
F2: Includes shares of common stock underlying unvested restricted stock units.
F3: The number of reported securities has been adjusted to reflect prior reverse stock splits.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2026 Filed Feb 6, 2026 13:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 16,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-000811 · ownership.xml · nonDerivative · entry 1 Freeman Jonathan E · CIK 0001708133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,655 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F3 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 12:29 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 14,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-006958 · ownership.xml · nonDerivative · entry 1 Freeman Jonathan E · CIK 0001708133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,055 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F3 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 18:59 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $0.0001 par value | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-006375 · ownership.xml · nonDerivative · entry 1 Freeman Jonathan E · CIK 0001708133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:25 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011937 · doc4.xml · nonDerivative · entry 1 Freeman Jonathan E · CIK 0001708133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,197 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:08 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010396 · doc4.xml · nonDerivative · entry 1 Freeman Jonathan E · CIK 0001708133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,364 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 02:05 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017574 · doc4.xml · nonDerivative · entry 1 Freeman Jonathan E · CIK 0001708133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,364 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Effective as of 12:01 a.m. Eastern Time on January 15, 2020, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-55. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 02:11 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010830 · doc4.xml · nonDerivative · entry 1 Freeman Jonathan E · CIK 0001708133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| August 01, 2018 Filed Aug 4, 2018 01:36 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045460 · doc4.xml · nonDerivative · entry 1 Freeman Jonathan E · CIK 0001708133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 01:13 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantStock option (right to buy) · Derivative | 3,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-17-038449 · doc4.xml · derivative · entry 1 Freeman Jonathan E · CIK 0001708133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common stock · 3,500 shares Expires 2027-06-06 F1 · derivative.exercise_date: The stock option vests in equal quarterly installments over one year beginning on the first quarterly anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.